The Healthcare company, CannTrust Holdings Inc (TRST), has received a rating update from a Wall Street analyst yesterday. Analyst Ryan Macdonell from GMP FirstEnergy rated CannTrust Holdings Inc (TRST) a Hold, setting a C$6 price target.
According to TipRanks.com, Macdonell is ranked #2861 out of 5238 analysts.
Currently, the analyst consensus on CannTrust Holdings Inc is a Moderate Buy with an average price target of C$9.60, a 133.0% upside from current levels. In a report issued on July 8, Eight Capital also downgraded the stock to Hold with a C$6 price target.
.
The company has a one-year high of C$15.50 and a one-year low of C$4.05. Currently, CannTrust Holdings Inc has an average volume of 1.8M.
CannTrust Holdings, Inc. engages in the production and distribution of medical cannabis. It focuses on developing nanotechnology to create new products in the medical, recreational, beauty, wellness, and pet markets. The company was founded by Norman Paul and Eric Paul on March 16, 2015 and is headquartered in Vaughan, Canada.
The company’s shares closed on Wednesday at C$4.12, close to its 52-week low of C$4.05.
